関節リウマチにおけるエタネルセプトの有効性―インフリキシマブからの切り替え症例との比較―

スポンサーリンク

概要

• 論文の詳細を見る

• Objective: Tumor necrosis factor (TNF) is a key cytokine driving synovial inflammation in rheumatoid arthritis (RA), and the introduction of anti-TNF therapies has dramatically improved the treatment of active RA. Patients with RA who experience treatment failure with one an ti-tumor necrosis factor (anti-TNF) agent, whether because of lack of efficacy or toxicity, are frequently switched to a second anti-TNF agent. The aim of this study was to assess the efficacy of etanercept in RA as second-1ine therapy after infliximab in comparison with eternercept as first-line therapy,Methods: We assessed 74 patients with active RA treated with etanercept, 64 of whom received it as first-1ine therapy and 10 of whom received eternercept as second-line therapy after infliximab. EULAR response criteria and calculation of the DAS28 activity index at baseline and after 24 weekswere used to evaluate the efficacy of eternercept.Results: In the first-line therapy group, etanercept was stopped due because of toxicity in 3 cases and inefficacy in 2 cases. In the second-line therapy group, all patients were still being treated with etanercept at 24 weeks of follow up. A moderate or good response according to the EULAR criteria was achieved in 88.1% of the patients in the first-line therapy group, and in 70% in the second-line therapy group.Conclusion: The soluble tumor necrosis factor (TNF) receptor, etanercept provided a well tolerated and effective treatment option for some patients, even when infliximab was ineffective.

• 日本関節病学会の論文

日本関節病学会 | 論文

• 関節リウマチ患者における手術と機能回復
• 低出力超音波刺激(LIPUS)および線維芽細胞増殖因子(FGF-2)の骨形成促進作用におけるヒアルロン酸(HA)の影響
• 変形性関節症に対するグルコサミン・コンドロイチンの有用性 (第36回[日本関節病]学会寄稿)
• 人工膝関節再置換術の経験--脛骨結節骨切り術の適応と合併症について
• RA頚椎病変に対する上位頚椎後方除圧固定術の治療成績と問題点

もっと見る

スポンサーリンク